Tempest Therapeutics, Inc. ( (TPST)) has released its Q3 earnings. Here is a breakdown of the information Tempest Therapeutics, Inc. presented to its investors. Tempest Therapeutics, Inc. is a ...
For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...
Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback